TrialHaematologica2024

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.

Anastasios Stathis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.